ERBB2 and breast carcinoma: Since new treatment modalities, such as ERAD targeting, for Her2+ breast cancer patients are likely to enter the clinic in the heavily pre-treated patient populations, it is important that we understand the signaling and proteostasis dynamics during the process of cellular adaptation to anti-Her2 therapy.